CFTR opening depends on two regulatory events: phosphorylation and ATP binding. Phosphorylation prepares the channel for activation, while ATP binding supports the transition that permits chloride and bicarbonate passage. This sequence links cellular signaling and energy use to epithelial anion transport, so changes in either step can alter fluid balance across affected tissues.
The channel does not regulate secretions in isolation. CFTR coordinates with other channels and transporters, and that combined activity influences both the hydration and acidity of epithelial secretions. The consequences therefore extend beyond ion movement itself: altered coordination can change the physical and chemical environment of airway, intestinal, pancreatic, and reproductive tract secretions.
CFTR dysfunction can arise from problems with protein production, trafficking, gating, or stability. These categories describe distinct points at which normal channel activity may fail, from generating the protein to maintaining it in a usable form. Identifying the affected step is medically relevant because CFTR modulators are designed to target these specific functional defects.
Measuring CFTR activity provides functional information about whether the channel is operating adequately, rather than relying only on structural or clinical observations. In medicine, this assessment supports diagnosis by linking abnormal channel performance with disrupted epithelial ion transport. The result can help evaluate the functional basis of disease associated with impaired CFTR activity.
The effects vary across tissues because CFTR contributes to secretions in several epithelial organs. In the airways, poorly regulated fluid balance contributes to thick, poorly cleared secretions and pulmonary disease. Similar disruption in the gastrointestinal system can contribute to intestinal and pancreatic disease, while reproductive tract secretions may also be affected.
CFTR modulators address specific defects rather than treating all channel dysfunction as identical. Depending on the problem, therapy may target defective protein production, trafficking, gating, or stability. By improving the amount, location, activity, or persistence of functional CFTR, these treatments aim to improve epithelial secretion and organ function in affected patients.